Inhibition of S100β activity has been shown to mitigate intestinal damage and diarrhoea caused by C. difficile toxins, suggesting that targeting the production of S100β in EGCs could be a potential therapeutic strategy for managing the effects of CDI on the gastrointestinal system (97). This evidence concerns the gene S100B and clostridium difficile infection.